Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Ipsen
Woman and Man Max 99 years
Beaufour Ipsen Pharma
Update Il y a 4 ans
Effect of oral EGb 761® on Brain Glucose Metabolism in Three Groups of Elderly with Memory Complaint, mild Alzheimer's Disease, and Cognitively Normal Elderly. Phase II, randomised, double-blind, parallel groups, placebo-controlled study
To evaluate the effect of four weeks treatment with EGb761® in comparison to placebo in three groups of elderly : MC, AD and CNE. The primary endpoint will be the change in brain glucose metabolism ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Ipsen Pharma GmbH
Update Il y a 4 ans
Open, multicentre study on the equivalent efficacy and safety of Botulinum toxin A (500 Units Dysport®) in the treatment of heterogeneous forms of cervical dystonia
The results of a dose finding study have shown that 500 units Dysport® are the optimal starting dose for the treatment of patients with rotational torticollis. Although Dysport is an established first...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Ipsen
Update Il y a 4 ans
Étude RESILIENT : étude de phase 3 randomisée évaluant la sécurité, la tolérance de l’irinotécan liposomal et comparant son efficacité à celle du topotécan chez des patients ayant un cancer du poumon à petites cellules. [essai clos aux inclusions]
Le cancer du poumon à petites cellules représente 15 % des cancers du poumon diagnostiqués. Il y a deux types principaux de cancer du poumon à petites cellules : le carcinome à petites cellules et le ...
Country
France
organs
Poumon, type à petites cellules
Specialty
Chimiothérapie
Essai clos aux inclusions
More information
Woman Max 99 years
Ipsen Pharma (UK)
Update Il y a 4 ans
A prospective single-centre single-arm open-label study of the long-term use of a LHRH agonist (Decapeptyl SR 11.25mg) in combination with livial add-back therapy in the management of chronic cyclical pelvic pain in pre-menopausal women
Background and study aims Decapeptyl is a synthetic (man-made) hormone that stops the ovaries producing the hormone oestrogen. It can be used to treat disorders that are dependent on oestrogen being ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Beaufour Ipsen Pharma - 24, rue Erlanger 75016 Paris FRANCE
Update Il y a 4 ans
A phase II, open-label, multicentre study to evaluate the pharmacodynamic profile, the efficacy and the safety of a 6-month sustained-release formulation of triptorelin in patients with prostate cancer
To evaluate the pharmacodynamic profile of a 6-month sustained-release formulation of triptorelin administered as two simultaneous subcutaneous microimplant injections (2x6 mg) by measuring serum test...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Ipsen Innovation
Update Il y a 4 ans
A study looking at DYSPORT® for the treatment of subjects with loss of bladder control and involuntary urination caused by spinal cord injury or multiple sclerosis
• To assess the efficacy of two Dysport® doses (600 units (U) and 800 U), compared to placebo in reducing UI from Baseline to Week 6 following the first investigational medicinal product (IMP) adminis...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Ipsen
Update Il y a 6 ans
Étude SPINET : étude de phase 3 randomisée visant à comparer l’efficacité et la sécurité d’emploi du lanréotide au placebo en association aux meilleurs soins de support chez des patients ayant des tumeurs neuroendocrines du poumon typiques ou atypiques, bien différentiées, métastatiques et/ou non résécables.
Les tumeurs neuroendocrines prennent naissance dans les cellules du système neuroendocrinien qui sont dispersées dans tout le corps. Ces cellules reçoivent des signaux du système nerveux et fabriquent...
Country
France
organs
Appareil respiratoire - autres
Specialty
Thérapies Ciblées
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Ipsen Biopharm Ltd (UK) - provided Dysport®
Update Il y a 4 ans
Effect of botulinum toxin A injections and specific intensive rehabilitation therapy in children with hemiparetic cerebral palsy on upper limb functions and skills
Not provided at time of registration
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Ipsen Innovation
Update Il y a 4 ans
Efficacy and safety of lanreotide Autogel® 120 mg administered every 14 days in pancreatic or midgut neuroendocrine tumours having progressed radiologically while previously treated with lanreotide Autogel® 120 mg administered every 28 days Eficacia y seguridad de lanreotide Autogel® 120 mg administrado cada 14 días en tumores neuroendocrinos de intestino medio o pancreáticos que han progresado radiológicamente durante el tratamiento anterior con lanreotide Autogel® 120 mg administrado cada 28 días
To assess progression free survival (PFS) when treated with lanreotide Autogel® 120 mg administered every 14 days based on Response Evaluation Criteria in Solid Tumours (RECIST) v1.0, and according to...
Country
None
organs
None
Specialty
None
unknown
More information
Man Max 99 years
Ipsen Pharma
Update Il y a 4 ans
A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PROOF OF CONCEPT STUDY OF MAINTENANCE THERAPY WITH TASQUINIMOD IN PATIENTS WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER WHO ARE NOT PROGRESSING AFTER A FIRST LINE DOCETAXEL BASED CHEMOTHERAPY
To compare the clinical efficacy (i.e. radiological progression free survival [PFS]) of tasquinimod maintenance therapy with placebo in patients with metastatic castrate-resistant prostate cancer (mCR...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
Next